Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Kevin Bi(Broad Institute), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Grace Grimaldi(Broad Institute), Laura DelloStritto(Dana-Farber Cancer Institute), Steven L. Chang(Brigham and Women's Hospital), Angie Mayorga(Dana-Farber Cancer Institute), Meng Xiao He(Broad Institute), Abhay Kanodia(Dana-Farber Cancer Institute), Thomas Denize(Harvard University), Gabrielle Bouchard(Dana-Farber Cancer Institute), Ziad Bakouny(Dana-Farber Cancer Institute), Sébastien Vigneau(Broad Institute), Asaf Rotem(AstraZeneca (South Korea)), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Sabina Signoretti(Brigham and Women's Hospital), Toni K. Choueiri(Harvard University), Maxine Sun(Université de Montréal), Bradley A. McGregor(Harvard University), David A. Braun(Yale Cancer Center), Erin Shannon(Broad Institute), Orit Rozenblatt–Rosen(Broad Institute), Michael S. Cuoco(Broad Institute), Alok K. Tewari(Harvard University), Natalie I. Vokes(The University of Texas MD Anderson Cancer Center), Rizwan Haq(Ontario Institute for Cancer Research), Jihye Park(Broad Institute), Aviv Regev(Broad Institute), Jennifer L. Guerriero(Brigham and Women's Hospital), Sara Napolitano(Broad Institute)
Cancer Cell
March 12, 2021
Cited by 624


Related Papers